Linked Life Data

17485382

Source:http://linkedlifedata.com/resource/pubmed/id/17485382

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-5-8
pubmed:abstractText
Allogeneic stem cell transplantation (SCT) is an attractive form of immunotherapy for multiple myeloma (MM) due to well documented graft versus myeloma activity. High transplant related mortality with allogeneic SCT is currently the major limitation to wider use of this potentially curative modality. Mortality can be significantly reduced through the use of lower intensity conditioning regimens which allow engraftment of allogeneic stem cells. This comes at a cost, however, of higher rates of disease progression and relapse. Because allografting is currently the only modality with potential for cure, further studies designed to improve the therapeutic index of allografts are warranted. These include the use of intermediate intensity, yet still non-myeloablative conditioning regimens, autologous transplant performed just prior to allografting, peripheral blood cells, graft engineering to improve the graft versus myeloma activity while reducing GVHD, post transplant maintenance and targeted conditioning therapies such as bone seeking radioisotopes.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
1093-4715
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4384-92
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Reduced intensity allogeneic stem cell transplantation in multiple myeloma.
pubmed:affiliation
University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. wbensing@fhcrc.org
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural